Press releases

The results of the new investigator-initiated study titled "Effectiveness of Kinetic Oscillation Stimulation Treatment in Persistent Moderate-Severe...
The two incentive programs that were decided by Chordate Medical’s general meeting on May 11th, 2023, have today been signed in full by the company's...
Summary of the period January–March 2023 INCREASED ACTIVITY ON SEVERAL KEY MARKETSFrom the start of the year through May 2023, we have seen increased...
Chordate Medical Holding (publ) publishes its interim report for Q1 2023 on Thursday, May 25th, 2023, 08:30 a.m. On Friday, May 26th, 10:00 a.m., the company...
The investigator-initiated study The effect of single kinetic oscillation stimulation treatment on nonallergic rhinitis from the University of Helsinki...
Chordate Medical Holding AB (Publ.) (“Chordate” or “the Company”) held the Annual General Meeting on May 11th, 2023, whereby the...
The ethics committee of the National Health Service in the UK has approved the study design for Chordate Medical's upcoming migraine study PM009, which...
Saudi Arabia is one of the markets in which Chordate has been active for the longest time. Already in November 2020, private health insurance companies...
Chordate Medical has received an initial order for equipment and supplies to the treatment method K.O.S for chronic rhinitis via the company's distributor...
Dr. Emilia Tauriala is a specialist in neurology, Chief Medical Officer at Terveystalo – one of Finland's largest private healthcare companies, and...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact